This company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsVIOL（A335890）株式概要株式会社バイオルは、電気診断機器と医療機器を製造している。 詳細A335890 ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長5/6過去の実績0/6財務の健全性0/6配当金0/6報酬収益は年間22.62%増加すると予測されています リスク分析KR市場と比較して、過去 3 か月間の株価の変動が非常に大きいすべてのリスクチェックを見るA335890 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW480,409 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA480,409 investors already sharing narrativesYour Fair Value₩Current Price₩12.50k246.6% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-3b91b2016201920222025202620282031Revenue ₩90.6bEarnings ₩12.2bAdvancedSet Fair ValueView all narrativesVIOL Co., Ltd. 競合他社Next BiomedicalLtdSymbol: KOSDAQ:A389650Market cap: ₩308.7bWON TECHLtdSymbol: KOSDAQ:A336570Market cap: ₩475.7bTomocubeSymbol: KOSDAQ:A475960Market cap: ₩487.8bASTERASYSLtdSymbol: KOSDAQ:A450950Market cap: ₩227.6b価格と性能株価の高値、安値、推移の概要VIOL過去の株価現在の株価₩12,500.0052週高値₩27,500.0052週安値₩6,380.00ベータ01ヶ月の変化0%3ヶ月変化-0.16%1年変化59.44%3年間の変化321.59%5年間の変化378.93%IPOからの変化521.89%最新ニュースBoard Change • Dec 01Less than half of directors are independentThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). Part-time Inside Director Kim Kiyoung is the most experienced director on the board, commencing their role in 2023. Independent Part-time Outside Director Jeong-gwan Park was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors.Declared Dividend • Nov 08Dividend of ₩20.00 announcedDividend of ₩20.00 is the same as last year. Ex-date: 29th December 2025 Payment date: 24th April 2026 Dividend yield will be 0.2%, which is lower than the industry average of 1.8%. Sustainability & Growthお知らせ • Nov 07VIOL Co., Ltd. announces Annual dividend, payable on April 24, 2026VIOL Co., Ltd. announced Annual dividend of KRW 20.0000 per share payable on April 24, 2026, ex-date on December 29, 2025 and record date on December 31, 2025.New Risk • Sep 19New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.Price Target Changed • Apr 04Price target decreased by 7.2% to ₩11,420Down from ₩12,300, the current price target is an average from 5 analysts. New target price is 59% above last closing price of ₩7,190. Stock is down 29% over the past year. The company is forecast to post earnings per share of ₩376 for next year compared to ₩198 last year.お知らせ • Mar 12VIOL Co., Ltd., Annual General Meeting, Mar 25, 2025VIOL Co., Ltd., Annual General Meeting, Mar 25, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 744, pangyo-ro, bundang-gu, gyeonggi-do, seongnam South Korea最新情報をもっと見るRecent updatesBoard Change • Dec 01Less than half of directors are independentThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). Part-time Inside Director Kim Kiyoung is the most experienced director on the board, commencing their role in 2023. Independent Part-time Outside Director Jeong-gwan Park was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors.Declared Dividend • Nov 08Dividend of ₩20.00 announcedDividend of ₩20.00 is the same as last year. Ex-date: 29th December 2025 Payment date: 24th April 2026 Dividend yield will be 0.2%, which is lower than the industry average of 1.8%. Sustainability & Growthお知らせ • Nov 07VIOL Co., Ltd. announces Annual dividend, payable on April 24, 2026VIOL Co., Ltd. announced Annual dividend of KRW 20.0000 per share payable on April 24, 2026, ex-date on December 29, 2025 and record date on December 31, 2025.New Risk • Sep 19New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.Price Target Changed • Apr 04Price target decreased by 7.2% to ₩11,420Down from ₩12,300, the current price target is an average from 5 analysts. New target price is 59% above last closing price of ₩7,190. Stock is down 29% over the past year. The company is forecast to post earnings per share of ₩376 for next year compared to ₩198 last year.お知らせ • Mar 12VIOL Co., Ltd., Annual General Meeting, Mar 25, 2025VIOL Co., Ltd., Annual General Meeting, Mar 25, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 744, pangyo-ro, bundang-gu, gyeonggi-do, seongnam South KoreaPrice Target Changed • Feb 04Price target decreased by 7.0% to ₩12,300Down from ₩13,229, the current price target is an average from 7 analysts. New target price is 56% above last closing price of ₩7,890. Stock is up 7.3% over the past year. The company is forecast to post earnings per share of ₩376 for next year compared to ₩198 last year.Price Target Changed • Dec 17Price target decreased by 7.0% to ₩12,586Down from ₩13,533, the current price target is an average from 7 analysts. New target price is 53% above last closing price of ₩8,200. Stock is down 1.1% over the past year. The company is forecast to post earnings per share of ₩376 for next year compared to ₩198 last year.Valuation Update With 7 Day Price Move • Aug 05Investor sentiment deteriorates as stock falls 21%After last week's 21% share price decline to ₩8,070, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 13x in the Medical Equipment industry in South Korea. Total returns to shareholders of 235% over the past three years.Price Target Changed • May 12Price target increased by 10% to ₩12,000Up from ₩10,875, the current price target is an average from 4 analysts. New target price is 6.6% above last closing price of ₩11,260. Stock is up 82% over the past year. The company is forecast to post earnings per share of ₩376 for next year compared to ₩198 last year.Valuation Update With 7 Day Price Move • May 10Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₩11,260, the stock trades at a forward P/E ratio of 28x. Average forward P/E is 13x in the Medical Equipment industry in South Korea. Total returns to shareholders of 360% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩14,197 per share.分析記事 • May 09Here's Why We Think VIOL (KOSDAQ:335890) Is Well Worth WatchingInvestors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Buy Or Sell Opportunity • Apr 02Now 28% undervaluedOver the last 90 days, the stock has risen 15% to ₩10,360. The fair value is estimated to be ₩14,309, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 71% over the last year. Earnings per share has grown by 154%. Revenue is forecast to grow by 89% in 2 years. Earnings are forecast to grow by 115% in the next 2 years.Valuation Update With 7 Day Price Move • Mar 28Investor sentiment improves as stock rises 22%After last week's 22% share price gain to ₩10,140, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 12x in the Medical Equipment industry in South Korea. Total returns to shareholders of 375% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩14,295 per share.New Risk • Mar 14New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.Valuation Update With 7 Day Price Move • Mar 14Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩8,480, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 13x in the Medical Equipment industry in South Korea. Total returns to shareholders of 289% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩14,331 per share.分析記事 • Mar 01Why The 37% Return On Capital At VIOL (KOSDAQ:335890) Should Have Your AttentionDid you know there are some financial metrics that can provide clues of a potential multi-bagger? Ideally, a business...New Risk • Feb 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.Upcoming Dividend • Dec 20Upcoming dividend of ₩10.00 per share at 0.1% yieldEligible shareholders must have bought the stock before 27 December 2023. Payment date: 23 April 2024. Trailing yield: 0.1%. Lower than top quartile of South Korean dividend payers (3.5%). Lower than average of industry peers (1.6%).Buying Opportunity • Dec 05Now 21% undervaluedOver the last 90 days, the stock is up 27%. The fair value is estimated to be ₩10,718, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 71% over the last year. Earnings per share has grown by 154%. Revenue is forecast to grow by 99% in 2 years. Earnings is forecast to grow by 116% in the next 2 years.Valuation Update With 7 Day Price Move • Dec 01Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩9,590, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 13x in the Medical Equipment industry in South Korea. Total returns to shareholders of 277% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩10,842 per share.New Risk • Nov 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported March 2023 fiscal period end). Share price has been volatile over the past 3 months (8.5% average weekly change).New Risk • Nov 27New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. This is currently the only risk that has been identified for the company.Buying Opportunity • Aug 09Now 20% undervaluedOver the last 90 days, the stock is up 34%. The fair value is estimated to be ₩10,563, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 71% over the last year. Earnings per share has grown by 154%. Revenue is forecast to grow by 115% in 2 years. Earnings is forecast to grow by 116% in the next 2 years.Valuation Update With 7 Day Price Move • May 03Investor sentiment improves as stock rises 24%After last week's 24% share price gain to ₩6,130, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 14x in the Medical Equipment industry in South Korea. Total returns to shareholders of 205% over the past three years.Valuation Update With 7 Day Price Move • Apr 19Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩5,740, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 14x in the Medical Equipment industry in South Korea. Total returns to shareholders of 185% over the past three years.Buying Opportunity • Mar 23Now 20% undervaluedOver the last 90 days, the stock is up 63%. The fair value is estimated to be ₩5,713, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 69% over the last year. Earnings per share has grown by 149%. Revenue is forecast to grow by 125% in 2 years. Earnings is forecast to grow by 143% in the next 2 years.Reported Earnings • Mar 18Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2022 results: EPS: ₩198 (up from ₩80.00 in FY 2021). Revenue: ₩31.1b (up 69% from FY 2021). Net income: ₩11.5b (up 159% from FY 2021). Profit margin: 37% (up from 24% in FY 2021). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 6.4%. Earnings per share (EPS) missed analyst estimates by 4.6%. Revenue is forecast to grow 38% p.a. on average during the next 2 years, compared to a 7.1% growth forecast for the Medical Equipment industry in South Korea.Valuation Update With 7 Day Price Move • Feb 16Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₩5,150, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 12x in the Medical Equipment industry in South Korea. Total returns to shareholders of 152% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩4,730 per share.Valuation Update With 7 Day Price Move • Jan 17Investor sentiment improved over the past weekAfter last week's 18% share price gain to ₩3,780, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 10x in the Medical Equipment industry in South Korea. Total returns to shareholders of 88% over the past three years.Buying Opportunity • Nov 28Now 22% undervaluedOver the last 90 days, the stock is up 26%. The fair value is estimated to be ₩3,332, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue is forecast to grow by 139% in 2 years. Earnings is forecast to grow by 112% in the next 2 years.Reported Earnings • Nov 16Third quarter 2022 earnings released: EPS: ₩68.00 (vs ₩19.00 in 3Q 2021)Third quarter 2022 results: EPS: ₩68.00 (up from ₩19.00 in 3Q 2021). Revenue: ₩7.61b (up 66% from 3Q 2021). Net income: ₩3.94b (up 267% from 3Q 2021). Profit margin: 52% (up from 23% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 44% p.a. on average during the next 3 years, compared to a 3.2% growth forecast for the Medical Equipment industry in South Korea.お知らせ • Nov 11VIOL Co., Ltd. (KOSDAQ:A335890) announces an Equity Buyback for KRW 3,000 million worth of its shares.VIOL Co., Ltd. (KOSDAQ:A335890) announces a share repurchase program. Under the program, the company will repurchase up to KRW 3,000 million worth of its shares pursuant to a contract with KB Securities co.Ltd. The purpose of the share repurchase is to enhance shareholder value. The repurchase program will expire on May 13, 2023. As of November 10, 2022, the company had no shares within scope available for dividend and had 21 shares in treasury through other repurchase.Valuation Update With 7 Day Price Move • Oct 19Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₩1,990, the stock trades at a trailing P/E ratio of 14.5x. Average forward P/E is 10x in the Medical Equipment industry in South Korea. Total loss to shareholders of 5.2% over the past year.Valuation Update With 7 Day Price Move • Jun 23Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to ₩1,730, the stock trades at a trailing P/E ratio of 18.5x. Average trailing P/E is 11x in the Medical Equipment industry in South Korea. Total loss to shareholders of 30% over the past year.Is New 90 Day High Low • Mar 09New 90-day low: ₩2,180The company is down 12% from its price of ₩2,475 on 09 December 2020. The South Korean market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is down 5.0% over the same period.お知らせ • Nov 13Viol Co., Ltd. completed the acquisition of IBKS No.11 Special Purpose Acquisition Company (KOSDAQ:A335890) in a reverse merger transaction.Viol Co., Ltd. agreed to acquire IBKS No.11 Special Purpose Acquisition Company (KOSDAQ:A335890) in a reverse merger transaction on May 11, 2020. Under the terms of transaction the merger ratio is 1: 136.682. As per the amendments on September 7, 2020, the merger ratio was changed to 1: 124.875 (Ibks No.11 Spac Co., Ltd. : Viol Co., Ltd.). Post completion, DMS Co., Ltd., largest shareholder in Viol will own a 62.43% stake in the merged company. Through this merger, Viol Co., Ltd. will actually enjoy listing on the KOSDAQ market. The transaction is subject to approval of more than two-thirds of the voting rights of participating shareholders and one-third of the total number of shares issued in IBKS No.11. The transaction has been approved by the board of directors of IBKS No.11. The transaction is expected to close on October 12, 2020. As on July 16, 2020, the transaction is expected to close on November 2, 2020. As of September 7, 2020, the transaction was expected to close on November 11, 2020. Hanul Accounting Corporation acted as the accountant to IBKS No.11 Special Purpose Acquisition Company. Hyun Accounting Corporation acted as accountant to Viol Co., Ltd. Viol Co., Ltd. completed the acquisition of IBKS No.11 Special Purpose Acquisition Company (KOSDAQ:A335890) in a reverse merger transaction on November 12, 2020.株主還元A335890KR Medical EquipmentKR 市場7D0%-3.7%9.4%1Y59.4%-13.5%109.6%株主還元を見る業界別リターン: A335890過去 1 年間で-13.5 % の収益を上げたKR Medical Equipment業界を上回りました。リターン対市場: A335890は、過去 1 年間で109.6 % のリターンを上げたKR市場を下回りました。価格変動Is A335890's price volatile compared to industry and market?A335890 volatilityA335890 Average Weekly Movement21.2%Medical Equipment Industry Average Movement9.1%Market Average Movement9.8%10% most volatile stocks in KR Market17.6%10% least volatile stocks in KR Market5.1%安定した株価: A335890の株価は、 KR市場と比較して過去 3 か月間で変動しています。時間の経過による変動: A335890の 週次ボラティリティ は、過去 1 年間で10%から21%に増加しました。会社概要設立従業員CEO（最高経営責任者ウェブサイト2007n/aLee Sang Jinwww.viol.co.kr/enViol社は電気診断機器と医療機器を製造している。同社は2007年に設立され、韓国の城南に拠点を置く。もっと見るVIOL Co., Ltd. 基礎のまとめVIOL の収益と売上を時価総額と比較するとどうか。A335890 基礎統計学時価総額₩721.79b収益（TTM）₩14.29b売上高(TTM)₩35.49b0.0xPER（株価収益率0.0xP/SレシオA335890 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計A335890 損益計算書（TTM）収益₩35.49b売上原価₩8.87b売上総利益₩26.61bその他の費用₩12.32b収益₩14.29b直近の収益報告Mar 31, 2023次回決算日該当なし一株当たり利益（EPS）0グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率0.0%A335890 の長期的なパフォーマンスは？過去の実績と比較を見る配当金0.2%現在の配当利回りn/a配当性向A335890 配当は確実ですか？A335890 配当履歴とベンチマークを見るA335890 、いつまでに購入すれば配当金を受け取れますか？VIOL 配当日配当落ち日Dec 29 2025配当支払日Apr 24 2026配当落ちまでの日数233 days配当支払日までの日数117 daysA335890 配当は確実ですか？A335890 配当履歴とベンチマークを見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/12/10 14:59終値2025/12/09 00:00収益2023/03/31年間収益2022/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋VIOL Co., Ltd. 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。7 アナリスト機関Ji-Eun KimDB Financial Investment Co. Ltd.Yougun HanKB Securities Co., Ltd.Sion KangKorea Investment & Securities Co., Ltd.4 その他のアナリストを表示
Board Change • Dec 01Less than half of directors are independentThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). Part-time Inside Director Kim Kiyoung is the most experienced director on the board, commencing their role in 2023. Independent Part-time Outside Director Jeong-gwan Park was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors.
Declared Dividend • Nov 08Dividend of ₩20.00 announcedDividend of ₩20.00 is the same as last year. Ex-date: 29th December 2025 Payment date: 24th April 2026 Dividend yield will be 0.2%, which is lower than the industry average of 1.8%. Sustainability & Growth
お知らせ • Nov 07VIOL Co., Ltd. announces Annual dividend, payable on April 24, 2026VIOL Co., Ltd. announced Annual dividend of KRW 20.0000 per share payable on April 24, 2026, ex-date on December 29, 2025 and record date on December 31, 2025.
New Risk • Sep 19New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
Price Target Changed • Apr 04Price target decreased by 7.2% to ₩11,420Down from ₩12,300, the current price target is an average from 5 analysts. New target price is 59% above last closing price of ₩7,190. Stock is down 29% over the past year. The company is forecast to post earnings per share of ₩376 for next year compared to ₩198 last year.
お知らせ • Mar 12VIOL Co., Ltd., Annual General Meeting, Mar 25, 2025VIOL Co., Ltd., Annual General Meeting, Mar 25, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 744, pangyo-ro, bundang-gu, gyeonggi-do, seongnam South Korea
Board Change • Dec 01Less than half of directors are independentThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). Part-time Inside Director Kim Kiyoung is the most experienced director on the board, commencing their role in 2023. Independent Part-time Outside Director Jeong-gwan Park was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors.
Declared Dividend • Nov 08Dividend of ₩20.00 announcedDividend of ₩20.00 is the same as last year. Ex-date: 29th December 2025 Payment date: 24th April 2026 Dividend yield will be 0.2%, which is lower than the industry average of 1.8%. Sustainability & Growth
お知らせ • Nov 07VIOL Co., Ltd. announces Annual dividend, payable on April 24, 2026VIOL Co., Ltd. announced Annual dividend of KRW 20.0000 per share payable on April 24, 2026, ex-date on December 29, 2025 and record date on December 31, 2025.
New Risk • Sep 19New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
Price Target Changed • Apr 04Price target decreased by 7.2% to ₩11,420Down from ₩12,300, the current price target is an average from 5 analysts. New target price is 59% above last closing price of ₩7,190. Stock is down 29% over the past year. The company is forecast to post earnings per share of ₩376 for next year compared to ₩198 last year.
お知らせ • Mar 12VIOL Co., Ltd., Annual General Meeting, Mar 25, 2025VIOL Co., Ltd., Annual General Meeting, Mar 25, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 744, pangyo-ro, bundang-gu, gyeonggi-do, seongnam South Korea
Price Target Changed • Feb 04Price target decreased by 7.0% to ₩12,300Down from ₩13,229, the current price target is an average from 7 analysts. New target price is 56% above last closing price of ₩7,890. Stock is up 7.3% over the past year. The company is forecast to post earnings per share of ₩376 for next year compared to ₩198 last year.
Price Target Changed • Dec 17Price target decreased by 7.0% to ₩12,586Down from ₩13,533, the current price target is an average from 7 analysts. New target price is 53% above last closing price of ₩8,200. Stock is down 1.1% over the past year. The company is forecast to post earnings per share of ₩376 for next year compared to ₩198 last year.
Valuation Update With 7 Day Price Move • Aug 05Investor sentiment deteriorates as stock falls 21%After last week's 21% share price decline to ₩8,070, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 13x in the Medical Equipment industry in South Korea. Total returns to shareholders of 235% over the past three years.
Price Target Changed • May 12Price target increased by 10% to ₩12,000Up from ₩10,875, the current price target is an average from 4 analysts. New target price is 6.6% above last closing price of ₩11,260. Stock is up 82% over the past year. The company is forecast to post earnings per share of ₩376 for next year compared to ₩198 last year.
Valuation Update With 7 Day Price Move • May 10Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₩11,260, the stock trades at a forward P/E ratio of 28x. Average forward P/E is 13x in the Medical Equipment industry in South Korea. Total returns to shareholders of 360% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩14,197 per share.
分析記事 • May 09Here's Why We Think VIOL (KOSDAQ:335890) Is Well Worth WatchingInvestors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
Buy Or Sell Opportunity • Apr 02Now 28% undervaluedOver the last 90 days, the stock has risen 15% to ₩10,360. The fair value is estimated to be ₩14,309, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 71% over the last year. Earnings per share has grown by 154%. Revenue is forecast to grow by 89% in 2 years. Earnings are forecast to grow by 115% in the next 2 years.
Valuation Update With 7 Day Price Move • Mar 28Investor sentiment improves as stock rises 22%After last week's 22% share price gain to ₩10,140, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 12x in the Medical Equipment industry in South Korea. Total returns to shareholders of 375% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩14,295 per share.
New Risk • Mar 14New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
Valuation Update With 7 Day Price Move • Mar 14Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩8,480, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 13x in the Medical Equipment industry in South Korea. Total returns to shareholders of 289% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩14,331 per share.
分析記事 • Mar 01Why The 37% Return On Capital At VIOL (KOSDAQ:335890) Should Have Your AttentionDid you know there are some financial metrics that can provide clues of a potential multi-bagger? Ideally, a business...
New Risk • Feb 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
Upcoming Dividend • Dec 20Upcoming dividend of ₩10.00 per share at 0.1% yieldEligible shareholders must have bought the stock before 27 December 2023. Payment date: 23 April 2024. Trailing yield: 0.1%. Lower than top quartile of South Korean dividend payers (3.5%). Lower than average of industry peers (1.6%).
Buying Opportunity • Dec 05Now 21% undervaluedOver the last 90 days, the stock is up 27%. The fair value is estimated to be ₩10,718, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 71% over the last year. Earnings per share has grown by 154%. Revenue is forecast to grow by 99% in 2 years. Earnings is forecast to grow by 116% in the next 2 years.
Valuation Update With 7 Day Price Move • Dec 01Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩9,590, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 13x in the Medical Equipment industry in South Korea. Total returns to shareholders of 277% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩10,842 per share.
New Risk • Nov 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported March 2023 fiscal period end). Share price has been volatile over the past 3 months (8.5% average weekly change).
New Risk • Nov 27New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. This is currently the only risk that has been identified for the company.
Buying Opportunity • Aug 09Now 20% undervaluedOver the last 90 days, the stock is up 34%. The fair value is estimated to be ₩10,563, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 71% over the last year. Earnings per share has grown by 154%. Revenue is forecast to grow by 115% in 2 years. Earnings is forecast to grow by 116% in the next 2 years.
Valuation Update With 7 Day Price Move • May 03Investor sentiment improves as stock rises 24%After last week's 24% share price gain to ₩6,130, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 14x in the Medical Equipment industry in South Korea. Total returns to shareholders of 205% over the past three years.
Valuation Update With 7 Day Price Move • Apr 19Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩5,740, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 14x in the Medical Equipment industry in South Korea. Total returns to shareholders of 185% over the past three years.
Buying Opportunity • Mar 23Now 20% undervaluedOver the last 90 days, the stock is up 63%. The fair value is estimated to be ₩5,713, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 69% over the last year. Earnings per share has grown by 149%. Revenue is forecast to grow by 125% in 2 years. Earnings is forecast to grow by 143% in the next 2 years.
Reported Earnings • Mar 18Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2022 results: EPS: ₩198 (up from ₩80.00 in FY 2021). Revenue: ₩31.1b (up 69% from FY 2021). Net income: ₩11.5b (up 159% from FY 2021). Profit margin: 37% (up from 24% in FY 2021). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 6.4%. Earnings per share (EPS) missed analyst estimates by 4.6%. Revenue is forecast to grow 38% p.a. on average during the next 2 years, compared to a 7.1% growth forecast for the Medical Equipment industry in South Korea.
Valuation Update With 7 Day Price Move • Feb 16Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₩5,150, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 12x in the Medical Equipment industry in South Korea. Total returns to shareholders of 152% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩4,730 per share.
Valuation Update With 7 Day Price Move • Jan 17Investor sentiment improved over the past weekAfter last week's 18% share price gain to ₩3,780, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 10x in the Medical Equipment industry in South Korea. Total returns to shareholders of 88% over the past three years.
Buying Opportunity • Nov 28Now 22% undervaluedOver the last 90 days, the stock is up 26%. The fair value is estimated to be ₩3,332, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue is forecast to grow by 139% in 2 years. Earnings is forecast to grow by 112% in the next 2 years.
Reported Earnings • Nov 16Third quarter 2022 earnings released: EPS: ₩68.00 (vs ₩19.00 in 3Q 2021)Third quarter 2022 results: EPS: ₩68.00 (up from ₩19.00 in 3Q 2021). Revenue: ₩7.61b (up 66% from 3Q 2021). Net income: ₩3.94b (up 267% from 3Q 2021). Profit margin: 52% (up from 23% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 44% p.a. on average during the next 3 years, compared to a 3.2% growth forecast for the Medical Equipment industry in South Korea.
お知らせ • Nov 11VIOL Co., Ltd. (KOSDAQ:A335890) announces an Equity Buyback for KRW 3,000 million worth of its shares.VIOL Co., Ltd. (KOSDAQ:A335890) announces a share repurchase program. Under the program, the company will repurchase up to KRW 3,000 million worth of its shares pursuant to a contract with KB Securities co.Ltd. The purpose of the share repurchase is to enhance shareholder value. The repurchase program will expire on May 13, 2023. As of November 10, 2022, the company had no shares within scope available for dividend and had 21 shares in treasury through other repurchase.
Valuation Update With 7 Day Price Move • Oct 19Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₩1,990, the stock trades at a trailing P/E ratio of 14.5x. Average forward P/E is 10x in the Medical Equipment industry in South Korea. Total loss to shareholders of 5.2% over the past year.
Valuation Update With 7 Day Price Move • Jun 23Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to ₩1,730, the stock trades at a trailing P/E ratio of 18.5x. Average trailing P/E is 11x in the Medical Equipment industry in South Korea. Total loss to shareholders of 30% over the past year.
Is New 90 Day High Low • Mar 09New 90-day low: ₩2,180The company is down 12% from its price of ₩2,475 on 09 December 2020. The South Korean market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is down 5.0% over the same period.
お知らせ • Nov 13Viol Co., Ltd. completed the acquisition of IBKS No.11 Special Purpose Acquisition Company (KOSDAQ:A335890) in a reverse merger transaction.Viol Co., Ltd. agreed to acquire IBKS No.11 Special Purpose Acquisition Company (KOSDAQ:A335890) in a reverse merger transaction on May 11, 2020. Under the terms of transaction the merger ratio is 1: 136.682. As per the amendments on September 7, 2020, the merger ratio was changed to 1: 124.875 (Ibks No.11 Spac Co., Ltd. : Viol Co., Ltd.). Post completion, DMS Co., Ltd., largest shareholder in Viol will own a 62.43% stake in the merged company. Through this merger, Viol Co., Ltd. will actually enjoy listing on the KOSDAQ market. The transaction is subject to approval of more than two-thirds of the voting rights of participating shareholders and one-third of the total number of shares issued in IBKS No.11. The transaction has been approved by the board of directors of IBKS No.11. The transaction is expected to close on October 12, 2020. As on July 16, 2020, the transaction is expected to close on November 2, 2020. As of September 7, 2020, the transaction was expected to close on November 11, 2020. Hanul Accounting Corporation acted as the accountant to IBKS No.11 Special Purpose Acquisition Company. Hyun Accounting Corporation acted as accountant to Viol Co., Ltd. Viol Co., Ltd. completed the acquisition of IBKS No.11 Special Purpose Acquisition Company (KOSDAQ:A335890) in a reverse merger transaction on November 12, 2020.
